Sindromi Mieloproliferative Croniche Ph -
Confronto real Word e Studi registrativi
Myeloproliferative Neoplasms (MPN): WHO 2016

- Chronic myeloid leukemia (CML), BCR-ABL1
- Chronic neutrophilic leukemia (CNL)
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
  - PMF, prefibrotic/early stage
  - PMF, overt fibrotic stage
- Essential Thrombocythemia (ET)
- Chronic eosinophilic leukemia, not otherwise specified (NOS)
- MPN, unclassifiable

Arber A et al, Blood 2016; 12:2391-2405
MIELOFIBROSI PRIMARIA E SECONDARIA

MPN Ph-

- Trombocitemia essenziale (ET)
- Policitemia vera (PV)

Mielofibrosi primaria

Mielofibrosi "idiopatica" cioè senza causa apparente

Mielofibrosi secondaria

Post-PV o post-ET

10-15% dei casi
Evoluzione di una precedente PV o ET che avviene generalmente dopo molti anni di malattia,

Leucemia mieloide acuta (AML)

# Diagnostic Criteria of PMF

- **WHO2016**

<table>
<thead>
<tr>
<th>Pre-PMF</th>
<th>Overt PMF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Major criteria</strong></td>
<td><strong>Major criteria</strong></td>
</tr>
<tr>
<td>1. BM biopsy with Mk proliferation and atypia, w/o reticulin fibrosis &gt;G1; with incr. cellularity, granulocytic prolifer and often decreased erythropoiesis</td>
<td>1. BM biopsy with Mk proliferation and atypia with either reticulin fibrosis G2-3 and/or collagen</td>
</tr>
<tr>
<td>2. Not meeting WHO criteria for other myeloid neoplasms</td>
<td>2. Not meeting WHO criteria for other myeloid neoplasms</td>
</tr>
<tr>
<td>3. Presence of JAK2V617F, CALR or MPL mutation, or in the absence of these mutations, presence of another clonal marker, or absence of minor reactive BM reticulin</td>
<td>4. Presence of JAK2V617F, CALR or MPL mutation, or in the absence of these mutations, presence of another clonal marker, or absence of reactive myelofibrosis</td>
</tr>
<tr>
<td><strong>Minor criteria</strong></td>
<td><strong>Minor criteria</strong></td>
</tr>
<tr>
<td>1. Anemia</td>
<td>1. Anemia</td>
</tr>
<tr>
<td>2. Leucocytosis &gt;11x10⁹/L</td>
<td>2. Leucocytosis &gt;11x10⁹/L</td>
</tr>
<tr>
<td>3. Palpable splenomegaly</td>
<td>3. Palpable splenomegaly</td>
</tr>
<tr>
<td>4. Increased LDH</td>
<td>4. Increased LDH</td>
</tr>
<tr>
<td>5. Leukocytosis &gt;11x10⁹/L</td>
<td>5. Leukocytosis &gt;11x10⁹/L</td>
</tr>
</tbody>
</table>

\$3 \text{ major } + \geq 1 \text{ minor}\$  
\$3 \text{ major } + \geq 1 \text{ minor}\$

In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (eg, *ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, SF3B1*) are of help in determining the clonal nature of the disease.

Arber DA et al, Blood 2016; 127:2391-405
Reproducibility of WHO criteria for prePMF
Studies with formal assessment of concordance between pathologists

<table>
<thead>
<tr>
<th>Study</th>
<th>Consensus</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbui, T et al., 2011</td>
<td>81 %</td>
<td>1,104</td>
</tr>
<tr>
<td>J Clin Oncol, 29:3179-84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiele, J et al., 2011</td>
<td>88 %</td>
<td>295</td>
</tr>
<tr>
<td>Blood, 117:5710-5718</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gisslinger, H et al., 2013</td>
<td>83 %</td>
<td>259</td>
</tr>
<tr>
<td>Blood, 121:1720-1728</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madelung, AB et al., 2013</td>
<td>83 %</td>
<td>272</td>
</tr>
<tr>
<td>Am J Hematol, 88:1012-1016</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gianelli U, et al., 2013</td>
<td>76 %</td>
<td>103</td>
</tr>
<tr>
<td>Mod Pathol, PMID: 24201120</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Overall consensus** 82 % 2,033

<table>
<thead>
<tr>
<th>Study</th>
<th>Consensus</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilkens, BS et al., 2008</td>
<td>53 %</td>
<td>370</td>
</tr>
<tr>
<td>Blood, 111:60-70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brousseau, M et al., 2010</td>
<td>65 %</td>
<td>127</td>
</tr>
<tr>
<td>Histopathology, 56:758-767</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koopmans SM, et al., 2011</td>
<td>70 %</td>
<td>56</td>
</tr>
<tr>
<td>Am J Clin Pathol, 136:618-624</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buhr T, et al., 2012</td>
<td>62 %</td>
<td>102</td>
</tr>
<tr>
<td>Haematologica, 97:360-365</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Overall consensus** 63 % 655

Additional studies supporting validity of the WHO criteria (n=736)

<table>
<thead>
<tr>
<th>Study</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Florena, AM et al., 2004, Haematologica, 89:911-919</td>
<td>142</td>
</tr>
<tr>
<td>Kreft, A et al., 2005, Acta Haematol., 113: 137-143</td>
<td>275</td>
</tr>
<tr>
<td>Gianelli, U et al., 2006, Leuk. Lymphoma, 47:1774-1781</td>
<td>116</td>
</tr>
<tr>
<td>Vener, C et al., 2008, Blood, 111:1862-1865</td>
<td>113</td>
</tr>
<tr>
<td>Ejerblad E et al., 2013, Hematology, 18:8-13</td>
<td>40</td>
</tr>
</tbody>
</table>
Chi si ammala? Quando ci si ammala? È una malattia frequente?

- Lo studio della frequenza e della distribuzione di una malattia a livello di popolazione si definisce “epidemiologia”.

- La frequenza di una malattia si può misurare in due modi: statico e dinamico

**Misura statica: PREVALENZA**

- tutti i casi esistenti in un certo momento e in una certa popolazione

- quanti sono oggi i casi di mielofibrosi per ogni 100.000 persone?

**Misura dinamica: INCIDENZA**

- numero di **nuovi casi** che si verificano in una certa popolazione in un certo intervallo di tempo

- nell’arco di un anno, quanti sono i **nuovi casi** di mielofibrosi per ogni 100.000 persone?
EPIDEMIOLOGIA - DATI ATTUALI

Epidemiologia

Prevalenza:
Da 1 a 9 casi su 100.000

Incidenza:
Da 0,5 a 1,5 nuovi casi su 100.000 soggetti all’anno

Età alla diagnosi:
nella maggior parte dei casi colpisce pazienti tra i 60 e i 70 anni di età. Nel 15% dei casi può interessare persone con meno di 55 anni, mentre i casi pediatrici sono rarissimi

Sesso:
Non vi è prevalenza di sesso

Study Design

Seven international centers

Inclusion criteria:
local ET diagnosis (from 1975 to 2008) and pre-treatment Bone Marrow biopsy obtained at time of diagnosis (or within 1 year of diagnosis in untreated patients)

1,104 ET patients
WHO 2008 review by WHO author (JT)
completely blinded to outcome data

True ET Early MF

Barbui T et al, JCO 2011; 29:3179-84.
FINAL ASSIGNMENT IN 1104 PATIENTS PRESENTING WITH ET

ET cases 891 (81%)

Early MF cases 180 (16%)

Others* 33 (3%)

*(were inadequate or reactive cases)

Agreement between pathologists was 83% for discriminating ET from early/prefibrotic PMF
Clinical Outcome in Young Adults with ET versus Early/prefibrotic Myelofibrosis

The rates of composite outcomes (thrombosis, bleeding, and evolution to overt MF) were significantly higher in early PMF than in WHO-ET patients (3.43% vs 1.29% of patients/year, respectively).

Barbui T et al. Blood 2012;120:569-571
COMFORT Trials (5-yrs follow up)

COMFORT-I

Patients with MF (N = 309) Randomized 1:1

- Ruxolitinib 15-20 mg BID (n=155) 41.9%
- Placebo (n=151) 0.7%

Primary Endpoint
- Subjects achieving ≥35% reduction in spleen volume from baseline to week 24

Secondary Endpoint
- Proportion of patients with ≥50% reduction in Total Symptom Score (mod. MFSAF v2.0)

COMFORT-II

Patients with MF (N = 219) Randomized 2:1

- Ruxolitinib 15-20 mg BID (n=146) 28.5%
- Best available therapy (n=173) 0%

Primary Endpoint
- Subjects achieving ≥35% reduction in spleen volume from baseline to week 48

Secondary/Exploratory endpoints
- Changes in functioning and symptoms

Current status: ruxolitinib in MF

- A highly effective drug benefitting many patients (53% of spleen response at any time in COMFORT-II)
- Consolidated data from 2233 patients in the JUMP trial
- Anemia (gr 3-4:22%) and especially thrombocytopenia (gr 3-4:15%) may limit effective dosing
Studio di fase 2 per valutare l’efficacia e la sicurezza di Ruxolitinib in pazienti con mielofibrosi ed anemia (studio REALISE)

PMF, PPV=MF, PET=MF

1. Anemia
   Hb<10g/dl
2. PLT>50x10^9/L
3. Milza palpabile
   >5cm
4. Blasti SP ≤ 10%

12 settimane
16 settimane

Ruxolitinib 10mg x 2/die

Riduzione del 50% dalla milza

SI

- PLT 100-200 x 10^9/L
  Ruxolitinib 15 mg x 2/die
- PLT >200 x 10^9/L
  Ruxolitinib 20 mg x 2/die

COMFORTI (5yrs follow-up)

Volume della mitza

Sintomi
Current status: ruxolitinib in MF

- A highly effective drug benefitting many patients (53% of spleen response at any time in COMFORT-II)
- Consolidated data from 2233 patients in the JUMP trial
- Anemia (gr 3-4:22%) and especially thrombocytopenia (gr 3-4:15%) may limit effective dosing
- Infections are more frequent
- Lack of current evidence of benefit from early disease with aim of disease moderation
- Definition of failure variable in clinical trials, unclear in clinical practice
Ruxolitinib and OS: results from COMFORT-II

Median Overall Survival
- Ruxolitinib = Not Reached
- BAT (ITT) = 4.1 years
- BAT (RPSFT) = 2.7 years

K-M estimated probability of OS at 5 yrs: 56% with Ruxolitinib and 44% with BAT

Harrison CN et al; Leukemia 2016;30;1701-7
MF treatment algorithm

ESMO 2015 guidelines

Primary, post-ET and post-PV myelofibrosis

Calculate IPSS score*

Low risk & Int-1

Symptomatic

No

- Observation
- Ruxolitinib***

Yes

- Conventional treatment**

Int-2 & High risk

AlloSCT eligible?

No

- Ruxolitinib
- Drugs for anaemia
- Clinical trial

Yes

- Conventional
- Reduced intensity

* Vannucchi et al, 2015, ESMO guidelines
IPSS low/Int-1 patients may have burdensome symptoms with impact on QoL

Lower DIPSS patients may be symptomatic in 44% of cases

QoL, work and social impairment is similar in lower and higher risk categories

Total Symptom Score is significantly associated with spleen length

A single MPN10 symptom value >5/10 has been suggested as predictive for higher DIPSS and for patients who could benefit from treatment

ELN/SIE evidence based recommendations

- **Ruxolitinib is recommended for improving splenomegaly in:**
  - Patients with int2-high risk and either symptomatic or severe splenomegaly (strong recommendation)
  - Patients with int1 risk and either symptomatic or severe splenomegaly not responsive or intolerant to HU or IFN (weak recommendation)
  - Patients with int1 risk and both symptomatic or severe splenomegaly not previously treated with any cytoreductive agent (weak recommendation)

- **Ruxolitinib is recommended for improving symptoms in:**
  - Patients with a MPN10 score > 44 or refractory itching (score >6) or unintended weight loss (>10% in the past 6 months) not attributable to other causes or unexplained fever (strong recommendation)
Even the early stages may have prognostically unfavourable mutations

- Approximately 40% of intermediate-1 risk patients are at high molecular risk (HMR),¹ associated with poor prognosis²
- These are patients who may require early intervention

Guglielmi et al. Blood 2017;129:3227-3236
Italian multicentric study on 408 patients

<table>
<thead>
<tr>
<th>Caratteristiche</th>
<th>Pazienti (n. 408)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sesso maschile, no. (%)</td>
<td>230 (56.4%)</td>
</tr>
<tr>
<td>Mielofibrosi primaria, no (%)</td>
<td>222 (54.4%)</td>
</tr>
<tr>
<td>Età &gt;65 anni, no (%)</td>
<td>259 (63.5%)</td>
</tr>
<tr>
<td>IPSS intermedio-2/alto, no (%)</td>
<td>344 (84.3%)</td>
</tr>
<tr>
<td>Emoglobina g/dl (range)</td>
<td>10.7 (7-16.7)</td>
</tr>
<tr>
<td>Anemia trasfusione dipendente</td>
<td>114 (27.9%)</td>
</tr>
<tr>
<td>Piastrine, x10^9/l (range)</td>
<td>257 (50-1887)</td>
</tr>
<tr>
<td>Sintomi costituzionali, no (%)</td>
<td>220 (53.9%)</td>
</tr>
<tr>
<td>Total symptoms score (TSS)</td>
<td>20 (12-70)</td>
</tr>
<tr>
<td>Milza palpabile, no (%)</td>
<td>394 (96.6%)</td>
</tr>
<tr>
<td>Milza ≥ 10 cm dal MCS</td>
<td>262 (64.2%)</td>
</tr>
<tr>
<td>JAK29377f mutation, no (% su 347)</td>
<td>281 (81.0%)</td>
</tr>
<tr>
<td>Cariotipo sfavorevole, no (% su 212)</td>
<td>17 (8.0%)</td>
</tr>
<tr>
<td>Fibrosi midollare grado 3 , no (% su 378)</td>
<td>108 (28.6%)</td>
</tr>
<tr>
<td>Tempo MF-inizio ruxo &gt;2 anni, no (%)</td>
<td>185 (45.3%)</td>
</tr>
</tbody>
</table>

- Caratteristiche principali all’inizio del trattamento con ruxolitinib:
  - Rischio IPSS Intermedio 2/alto (84.3%)
  - Sintomi costituzionali (53.9%)
  - Splenomegalia> 10 cm (64.2%)

- 27.9% anemia trasfusione dipendente
- Dose iniziale media=20 mg BID (7.3% 10 mg BID)
- Tempo mediano, tra diagnosi di MF e inizio ruxolitinib, 18 mesi (1-344)
- Follow-up mediano dalla diagnosi di MF, 3.8 anni (0.3-29.2)
- Mediana di esposizione a ruxolitinib, 20 mesi (3-56.2)

Pallandri F et al, Oncotarget 2017
Time to ruxolitinib impacts on response

The probability of spleen response was significantly inferior in patients with a more advanced MF and in patients who started ruxolitinib later.
Spleen and TSS response with dosage

**RUX starting dose**
- 5 BID n. 37: 21.6%
- 10-15 BID n. 112: 26.8%
- 20 BID n. 176: 42.7%

**Titrated 12-wks RUX dose**
- 5 BID n. 63: 22.2%
- 10 BID n. 60: 35.0%
- 15 BID n. 93: 34.4%
- 20 BID n. 111: 42.3%

**TSS responders (%)**
- 5 BID n. 33: 81.8%
- 10-15 BID n. 110: 88.2%
- 20 BID n. 201: 84.6%

**Titrated 12-wks RUX dose**
- 5 BID n. 64: 84.4%
- 10 BID n. 61: 85.2%
- 15 BID n. 99: 86.9%
- 20 BID n. 120: 85.0%

Palandri F et al, Oncotarget 2017
Can Ruxolitinib modify the pathogenesis of the disease?

- Modification of allele burden in the COMFORT studies especially in patients that have a short time from the diagnosis

<table>
<thead>
<tr>
<th>Last available postbaseline fibrosis grade</th>
<th>Ruxolitinib (n = 146)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Fibrosis Grade, n (%)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>1 (0.7) 1 (0.7) 2 (1.4) 1 (0.7) 2 (1.4)</td>
</tr>
<tr>
<td>1</td>
<td>0 10 (6.8) 9 (6.2) 2 (1.4) 0</td>
</tr>
<tr>
<td>2</td>
<td>0 2 (1.4) 8 (5.5) 8 (5.5) 1 (0.7)</td>
</tr>
<tr>
<td>3</td>
<td>0 6 (4.1) 19 (13.0) 28 (19.2) 2 (1.4)</td>
</tr>
<tr>
<td>Missing</td>
<td>2 (1.4) 2 (1.4) 17 (11.6) 20 (13.7) 3 (2.1)</td>
</tr>
</tbody>
</table>

- BM fibrosis modification due to a probable effect on the medullary microenvironment

JUMP study: treatment for intermediate-1 risk pts

- 163 interm-1 risk pts (median age 62 years, range 25-79)
- Median time form diagnosis 17.9 mos (range 0.2-276 mos)
- 76% of pts remained on treatment, 65% with 20 mg BID
- 64% pts modified the dose
- Similar toxicity profile as to interm2/high risk (anemia 54% all grades, 24.5% grade 3/4, thrombocytopenia 40.5% all grades, 11% grade 3/4

- At 72 weeks, 77.6% pts ha reduced > 50% of splenomegaly with 21% of CR.
- No differences of efficacy between 20 mg and 15 mg BID

Al-Alli et al, Haematologica 2016
JUMP: improvement of symptoms in int-1 risk pts

FACT-Lymphoma Total Score

- Week 4: 60/148 (40.5%)
- Week 12: 53/140 (37.9%)
- Week 24: 44/129 (34.1%)
- Week 48: 32/106 (30.2%)

FACIT-Fatigue Scale

- Week 4: 70/149 (47.0%)
- Week 12: 56/139 (40.3%)
- Week 24: 54/130 (41.5%)
- Week 48: 35/102 (34.3%)

The MYSEC-PM estimate of survival in SMF

- **Low risk (n=133), not reached**
- **Int-1 risk (n=245), 9.3 years (95% CI: 8.1-NR)**
- **Int-2 risk (n=126) 4.4 (95% CI: 3.2-7.9)**
- **High risk (n=75), 2 years (95% CI: 1.7-3.9)**

**Patients at risk:**
- Low: 133, 245, 126, 75
- Intermediate-1: 133, 245, 126, 75
- Intermediate-2: 133, 245, 126, 75
- High: 133, 245, 126, 75

**SMF Follow-up time (years):**
- Low: 0, 2, 4, 6, 8, 10, 12, 14
- Intermediate-1: 0, 2, 4, 6, 8, 10, 12, 14
- Intermediate-2: 0, 2, 4, 6, 8, 10, 12, 14
- High: 0, 2, 4, 6, 8, 10, 12, 14

Treatment of MF – general overview

- All patients are very different: the treatment needs to be tailored to an individual patient’s symptoms and circumstances
- Some patients may not need treatment for several years, others are very unwell at diagnosis and need treatment straight away
- Stem cell transplantation is the only potentially curative strategy – but only a small minority of patients are suitable
- For all other patients – the primary aim of current drug treatments are symptom control and improving quality of life
MF treatment algorithm

ESMO 2015 guidelines

Primary, post-ET and post-PV myelofibrosis

Calculate IPSS score

Low risk & Int-1
- Symptomatic
  - No: Observation
  - Yes: Conventional treatment
    - Ruxolitinib

Int-2 & High risk
- AlloSCT eligible?
  - No: Ruxolitinib
    - Drugs for anaemia
    - Clinical trial
  - Yes: AlloSCT
    - Conventional
    - Reduced intensity

Vannucchi et al, 2015, ESMO guidelines
Cooperative Italian study for interm-1 risk (II)

- +3 mos responses: 41% splenic responses, 72.5% symptoms response
- +6 mos: 54.7% splenic responses, 80% symptoms response
- After a median FU of 27 mos, 39% of pts maintained the response
- 80.6% of pts maintained the dose > 15 mg BID

(A) 60% splenic response as best response at 24 mos

(B) 90% symptoms response in the first 2 mos

Palandri et al, Hematol Oncol 2017
2018 ELN Recommendations on the Management of Myelofibrosis

Asymptomatic patients with low- or intermediate-1 risk disease:

- Observation alone for IPSS/DIPSS/DIPSS-plus low- or intermediate-1 MF risk patients who lack significant symptoms, and who do not display significant anemia, splenomegaly, leukocytosis, or marked thrombocytosis.
- If cytoreductive treatment for the reduction of leukocytosis or thrombocytosis is indicated, the first-line drug of choice is hydroxyurea.

Treatment of MF-associated anemia

- The choice of a specific drug for MF-associated anemia should be based on overall toxicity profile and its expected risk in the individual patient (Androgen, Thalidomide).
- In patients with transfusion dependency, a low rate of response to epoetins is expected, therefore the risk/benefit of a therapeutic use with epoetins is questionable.
- Lenalidomide use is justified in cases with the presence of del(5q31).
- There is currently not enough evidence to recommend combination therapy for MF-associated anemia, other than the addition of a short course of prednisone therapy to treatment with thalidomide.

2018 ELN Recommendations on the Management of Myelofibrosis

**Treatment of MF-associated splenomegaly**

Ruxolitinib is recommended as first-line approach for MF-associated splenomegaly in patients with intermediate-2 or high-risk disease. In patients with intermediate-1 risk disease and highly symptomatic splenomegaly, first-line therapy is ruxolitinib. In other patients with intermediate-1 risk disease, and in those with low-risk disease in need of therapy for MF-associated splenomegaly, hydroxyurea is recommended as first-line therapy. Ruxolitinib is also recommended for reducing splenomegaly in patients with splenomegaly not responding or intolerant to hydroxyurea.

**Splenectomy**

Splenectomy remains a viable palliative treatment option for drug-refractory symptomatic splenomegaly and may be considered when drug-induced anemia hampers the effective use of hydroxyurea or ruxolitinib.

2018 ELN Recommendations on the Management of Myelofibrosis

Allogeneic stem cell transplantation

We recommend considering allogeneic stem cell transplant for all transplant-eligible patients with IPSS/DIPSS/DIPSS-plus high or intermediate-2 risk.
The Panel also recommended consideration of allogeneic stem cell transplantation for transplant eligible patients with IPSS/DIPSS/DIPSS Plus intermediate-1 risk score who present with either refractory, transfusion-dependent anemia, or a percentage of blasts in peripheral blood >2% in at least two repeated manual measurements, or adverse cytogenetics, or high-risk mutations.
In this situation, the transplant procedure should be performed in a controlled setting (registries, clinical trial).

Fin qui abbiamo

- Ruxolitinib è meglio che niente
- Ruxolitinib è meglio che qualsiasi altra terapia
- Ruxolitinib ha un’efficacia maggiore in stadi più precoci malattia
- Ruxolitinib è entrato nella terapia ormai consolidata del paziente ad alto rischio e si inserisce ormai sempre più frequentemente come terapia del paziente a rischio intermedio o basso e anche come preparazione al trapianto
Ma quale il limite nella vita reale

- Il problema dell’anemia
- Il problema della leucocitosi
- Il problema della piastrinopenia
- L’efficacia nelle mielofibrosi non splenomegaliche
Studio Romei

• Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI)

• Massimo Breccia1, Paola Guglielmelli2, Alessandra Malato3, Francesco Mendicino4, Giuseppe Palumbo5, Carmine Selleri6, Daniela Cilloni7, Patrizio Mazza8, Sergio Siragusa9 Elisabetta Abruzzese10, Robin Foa11, Monica Crugnola12, Domenico Pastore13, Serena Rupoli14, Umberto Vitolo15, Mara Morelli16, Francesca Palandri17 and Francesco Passamonti18.
ROMEI

- ROMEI (CINC424AIT04 Ruxolitinib Observational study in Myelofibrosis treated Patients in Italy) is a prospective observational study that aims to bridge the knowledge gap between the clinical experience of registration trials and routine patient management by following roughly 200 myelofibrosis (MF) patients (pts) treated with ruxolitinib in everyday clinical practice. Enrollment began in April 2017 and ended in May 2018.
ROMEI

- The primary endpoint is to evaluate changes in symptoms and quality of life during treatment with ruxolitinib through the Myeloproliferative Neoplasm 10 (MPN-10) disease-specific questionnaire and EuroQoL-5D-5L (EQ-5D-5L) general health questionnaire. Secondary endpoints: spleen length (change from baseline in palpable spleen length from left costal margin), effects on bone marrow fibrosis, changes in patient-reported outcome (Myelofibrosis 7-Items Symptom Scale), overall survival (OS), adherence to treatment, safety and tolerability, and changes in work and productivity impairment. This first interim analysis evaluated only the primary endpoint, spleen length, OS and safety of the first pts with at least 24 weeks of exposure to ruxolitinib.
• Mean spleen length decreased from 9.78 ± 5.65 cm (range 0 - 24) at baseline to 4.97 ± 5.91 cm (range 0 - 24) at Visit 5, corresponding to a mean absolute change of -5.82 cm (95% CI: -7.23; -4.41 cm) and a percentage change of -58.56% (95% CI: -69.55; -47.57%). The proportion of patients with a > 50% reduction in palpable spleen length increased at each visit: 0.36 (95% CI: 0.24; 0.48) at Visit 2, 0.52 (95% CI: 0.39; 0.65) at Visit 3, 0.62 (95% CI: 0.50; 0.75) at Visit 4 and 0.64 (95% CI: 0.51; 0.77) at Visit 5. Best changes from baseline in spleen volume % in evaluable pts is show in Figure 1b.
Riduzione della milza
Preliminary data of the ROMEI study confirm the efficacy of ruxolitinib in everyday clinical practice in terms of symptom relief assessed through the MPN-10 and spleen response. The improvement from baseline observed in MPN 10 total score and the slight early improvement in EQ-5D-5L score at Week 24 may be partially related to the shorter median time from diagnosis to start of treatment (only 4 months) compared to that of pivotal or phase IIIb clinical trials.
Che cosa manca per la vita reale?

• Paziente di 70 anni con una storia di mielofibrosi primaria da 7 anni con milza all’ombelicale trasversa ed epatomegalia con varici esofagee saltuariamente sanguinanti, piastrinopenia (<60x10^3/uL), leucopenia e blasti circolanti 5%

• Trasfusioni o EPO in alternativa

• Ruxolitinib?
Che cosa manca per la vita reale?

- Paziente di 66 anni con alle spalle una storia di malattia di 5 anni con splenomegalia all’ombelicale trasversa, PLT 700x10^3/uL, WBC 25x10^3/uL, Hb 10.2.
- WBC in crescita
- Oncocarbide
- Ruxolitinib?
Cosa manca per la vita reale?

- Paziente di 73 anni testimone di Geova, Hb 6,7gr/dL, splenomegalia all’ombelicale trasversa, PLT 130x10^3/uL, WBC 3,2x10^3/uL
- Eritropoietina + bilancio del ferro
- Ruxolitinib?
Cosa manca per la vita reale?

• Quando è il timing corretto per le terapie di cui si dispone
• La miglior terapia va utilizzata all’inizio o alla fine?
• Fino a quando possiamo spingere con la terapia con Ruxolitinib?
• Quanto possono essere utili le combinazioni con oncocarbide o altro
• Eritropoietina e Ruxolitinib
COMFORT Trials (5-yrs follow up)

**COMFORT-I**
- Patients with MF (N = 309)
  - Randomized 1:1
  - Ruxolitinib 15 - 20 mg BID (n=155) 41.9%
  - Placebo (n=151) 0.7%

**Primary Endpoint**
- Subjects achieving ≥35% reduction in spleen volume from baseline to week 24

**Secondary Endpoint**
- Proportion of patients with ≥50% reduction in Total Symptom Score (mod. MFSAF v2.0)

**COMFORT-II**
- Patients with MF (N = 219)
  - Randomized 2:1
  - Ruxolitinib 15 - 20 mg BID (n=146) 28.5%
  - Best available therapy (n=173) 0%

**Primary Endpoint**
- Subjects achieving ≥35% reduction in spleen volume from baseline to week 48

**Secondary/Exploratory endpoints**
- Changes in functioning and symptoms

Considerazioni

• Paziente con mielofibrosi già con una storia di malattia e terapia ha il 41% di possibilità di sopravvivenza a 5 anni con Ruxolitinib e pressoché 0 chances senza farmaco

• Se somministriamo Ruxolitinib fin dalla prima diagnosi cosa succede?

• Il vero quesito ora è di sapere quanto è il tempo medio di perdita della risposta nei pazienti che hanno iniziato Ruxolitinib alla prima diagnosi